

<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		ATTY. DOCKET NO. 570024.402USPC		APPLICATION NO. 10/539,241			
		APPLICANTS Peixuan Guo et al.					
		FILING DATE September 5, 2007		GROUP ART UNIT 1635			
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1						

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. 570024.402USPC	APPLICATION NO. 10/539,241
	APPLICANTS Peixuan Guo et al.	
	FILING DATE September 5, 2007	GROUP ART UNIT 1635

### FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES      NO	
	1	1 366 151 B1	10/24/07	EP		
	2	WO 99/51755 A2	10/14/99	PCT		

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. 570024.402USPC	APPLICATION NO. 10/539,241
	APPLICANTS Peixuan Guo et al.	
	FILING DATE September 5, 2007	GROUP ART UNIT 1635

**NON-PATENT LITERATURE DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Akkina et al., "siRNAs, Ribozymes and RNA Decoys in Modeling Stem Cell-based Gene Therapy for HIV/AIDS" <i>Anticancer Res.</i> 23:1997-2005, 2003.
2	Ambrosini et al., "Induction of Apoptosis and Inhibition of Cell Proliferation by <i>survivin</i> Gene Targeting," <i>The Journal of Biological Chemistry</i> 273(18):11177-11182, 1998.
3	Bernstein et al., "Role for a bidentate ribonuclease in the initiation step of RNA interference," <i>Nature</i> 409:363-366, 2001.
4	Choi et al., "Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells," <i>Cancer Gene Therapy</i> 10(2):87-95, 2003.
5	Goldsby et al., <i>Immunology</i> , Fifth Edition, W.H. Freeman and Company, New York, 2003, Chapter 3, "Antigens," pp. 57-61.
6	Grossman et al., "Inhibition of melanoma tumor growth <i>in vivo</i> by survivin targeting," <i>Proc. Natl. Acad. Sci. USA</i> 98(2):635-640, 2001.
7	Guo, "Bacteriophage phi29 nanomotor pRNA as a carrier for breast cancer therapeutics," Grant Abstract BC024308. United States Department of Defense – Congressionally Directed Medical Research Programs. 2002 Breast Cancer Research Program Concept Award. Retrieved March 18, 2008 from <a href="http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&amp;type=public&amp;log_no=Bc024308">http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&amp;type=public&amp;log_no=Bc024308</a> . 1 page.
8	Guo, "Phi29 Hexameric Motor pRNA Nanoparticles as Polyvalent Vector for Prostate Cancer Detection and Specific Targeted Gene Delivery," Grant Abstract PC041144. United States Department of Defense – Congressionally Directed Medical Research Programs. 2004 Prostate Cancer Research Program Exploration – Hypothesis Development Award. Retrieved March 18, 2008 from <a href="http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&amp;type=public&amp;log_no=PC041144">http://cdmrp.army.mil/scripts/get_item.asp?item=abstract&amp;type=public&amp;log_no=PC041144</a> . 1 page.
9	Guo, "Nanotube and nanogold to gear phi29 DNA packaging motor," Grant Abstract 1R01EB003730-01. National Institute of Health – National Institute of Biomedical Imaging and Bioengineering, project dates September 1, 2004 to June 30, 2008. Retrieved March 18, 2008 from <a href="http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6794273&amp;p_grant_num=1R01EB003730-01&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6794273&amp;p_grant_num=1R01EB003730-01&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=</a> . 2 pages.
10	Guo, "Nanotube and nanogold to gear phi29 DNA packaging motor," Grant Abstract 5R01EB003730-02. National Institute of Health – National Institute of Biomedical Imaging and Bioengineering, project dates September 1, 2004 to June 30, 2008. Retrieved March 18, 2008 from <a href="http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6943946&amp;p_grant_num=5R01EB003730-02&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6943946&amp;p_grant_num=5R01EB003730-02&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=</a> . 2 pages.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. 570024.402USPC	APPLICATION NO. 10/539,241
	APPLICANTS Peixuan Guo et al.	
	FILING DATE September 5, 2007	GROUP ART UNIT 1635

**NON-PATENT LITERATURE DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

11	Guo, "Nanotube and nanogold to gear phi29 DNA packaging motor," Grant Abstract 5R01EB003730-03. National Institute of Health – National Institute of Biomedical Imaging and Bioengineering, project dates September 1, 2004 to June 30, 2008. Retrieved March 18, 2008 from <a href="http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7076251&amp;p_grant_num=5R01EB003730-03&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=.">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7076251&amp;p_grant_num=5R01EB003730-03&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=.</a> 2 pages.
12	Guo, "Nanotube and nanogold to gear phi29 DNA packaging motor," Grant Abstract 7R01EB003730-04. National Institute of Health – National Institute of Biomedical Imaging and Bioengineering, project dates September 1, 2004 to June 30, 2008. Retrieved March 18, 2008 from <a href="http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7245847&amp;p_grant_num=5R01EB003730-04&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=.">http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7245847&amp;p_grant_num=5R01EB003730-04&amp;p_query=&amp;ticket=59495470&amp;p_audit_session_id=300197806&amp;p_keywords=.</a> 2 pages.
13	Guo et al., "Corrigendum: Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells," <i>Gene Therapy</i> 13(21):1553, 2006.
14	Hood et al., "Tumor Regression by Targeted Gene Delivery to the Neovasculature" <i>Science</i> 296(5577):2404-2407, 2002.
15	Khaled et al., "Interleukin-3 Withdrawal Induces an Early Increase in Mitochondrial Membrane Potential Unrelated to the Bcl-2 Family – Roles of Intracellular pH, ADP Transport, and F <sub>0</sub> F <sub>1</sub> -ATPase," <i>J. Biol. Chem.</i> 276(9):6453-6462, 2001.
16	Khaled et al., "Lymphocide: Cytokines and the Control of Lymphoid Homeostasis," <i>Nat. Rev. Immunol.</i> 2:817-830, 2002.
17	Kim et al., "Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase," <i>Nat. Biotechnol.</i> 22:321-325, 2004.
18	Kim et al., "Characterization of an interleukin-7-dependent thymic cell line derived from a p53 <sup>-/-</sup> mouse," <i>J. Immunol. Methods</i> 274:177-184, 2003.
19	Kumar et al., "Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes," <i>Microbiol. Mol. Biol. Rev.</i> 62(4):1415-1434, 1998.
20	Kumar et al., "Apoptosis: A Cinderella Caspase Takes Center Stage," <i>Science</i> 297(5585):1290-1291, 2002.
21	Letai et al., "Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics," <i>Cancer Cell</i> 2:183-192, 2002.
22	Liu et al., "Identification and Characterization of Bim $\gamma$ , a Novel Proapoptotic BH3-only Splice Variant of Bim," <i>Cancer Research</i> 62(10):2976-2981, 2002.
23	Liu et al., "Phi29 pRNA Vector for Efficient Escort of Hammerhead Ribozyme Targeting Survivin in Multiple Cancer Cells," <i>Cancer Biology &amp; Therapy</i> 6(5):e1-e9, 2007.
24	Lu et al., "Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects," <i>J. Control Release</i> 91:17-29, 2003.
25	Luzi et al., "Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme," <i>Cancer Gene Therapy</i> 10:201-208, 2003.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. 570024.402USPC	APPLICATION NO. 10/539,241
	APPLICANTS Peixuan Guo et al.	
	FILING DATE September 5, 2007	GROUP ART UNIT 1635

**NON-PATENT LITERATURE DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	26		Madaio et al., "Responsiveness of Autoimmune and Normal Mice to Nucleic Acid Antigens," <i>J. Immunol.</i> 132(2):872-876, 1984.
	27		Novina et al., "siRNA-directed inhibition of HIV-1 infection," <i>Nat. Med.</i> 8(7):681-686, 2002.
	28		Soutschek et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> 432:173-178, 2004.
	29		Sudimack et al., "Targeted drug delivery via the folate receptor," <i>Advanced Drug Delivery Reviews</i> 41:147-162, 2000.
	30		Zong et al., "BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak," <i>Genes Dev.</i> 15(12):1481-1486, 2001.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	